A Differentiated Product Platform Company

To date, microbiome therapeutic strategies have focused primarily on adding or subtracting bacteria. Kaleido is the first company to use a chemistry-driven approach to systematically drive functional outputs of the microbiome. We have built a proprietary product platform for discovery and development that we believe will enable the rapid advancement of a broad portfolio of novel product candidates, Microbiome Metabolic Therapies, or MMTs. Our approach also has the potential to be faster and more cost efficient than traditional discovery and development.
MICROBIOME METABOLIC THERAPIES (MMT™):
Synthetic glycans that are structurally diverse and complex ensembles
Our library of 1,500+ MMTs:
  • Target enzymes across taxa rather than only in specific species, driving ecosystem and metabolic output changes
  • Related to a class of compounds that is Generally Recognized as Safe (GRAS), enabling rapid advancement into human clinical studies
  • Extensive IP; NCEs when developed as drugs
  • Orally administered with limited systemic exposure
  • Diversity of glycan library enables understanding of structure and disease pathways

Microbiome Metabolic Therapies (MMTs)

The microbiome is implicated in numerous diseases and health conditions. Learn how Kaleido is leading a differentiated approach to translating the promise of the microbiome into solutions for patients.

Discovery & Development Model

At Kaleido, we are breaking the mold of traditional discovery and development with a model that enables the rapid advancement into human clinical studies. These human clinical studies are conducted under regulations supporting research with food, evaluating safety, tolerability and potential markers of effect. For MMT candidates that are further developed as therapeutics, the Company conducts clinical trials under an Investigational New Drug (IND) or regulatory equivalent outside the U.S., and in Phase 2 or later development. Our approach has the potential to be faster and more cost efficient than traditional discovery and development. We initiated our first Phase 2 clinical trial under an IND for one of our MMT candidates approximately two years after conducting our first ex vivo screening.

The Microbiome—A Newly Discovered Organ with Largely Untapped Therapeutic Potential

The human microbiome is the community of more than 30 trillion microbes, organisms that include bacteria, viruses, archaea and fungi, which reside on and inside the human body. Over the last decade research has increased exponentially on the impact the microbiome has on human health, including cardiovascular disease, cancer, diabetes, Parkinson’s disease and allergies. This highly complex microbial ecosystem has been referred to as a “newly discovered organ.” Many other human organs command tens of billions of dollars for therapeutics that treat disease by modulating physiology. From a therapeutic perspective, the microbiome organ remains a largely untapped frontier in healthcare.

Publications & Presentations